The new drug for the treatment of wet or exudative maculopathy is called Brolucizumab.
It is produced by the Novartis company which has just announced the results of clinical trials in Vienna on the occasion of the Euretina congress from 20 to 23 September 2018. Brolucizumab has proven to be more effective than Aflibecert over time. Aflibecert is the drug currently on the market whose effectiveness is the longest lasting among all the drugs used in the treatment of maculopathy. Today the treatment of exudative maculopathy is based on the repeated execution of intravitreal injections. The new drug, Brolucizumab, seems to require intravitreal injections every 3 months and no longer every month like the most used drugs for the treatment of wet maculopathy. Brolucizumab (RTH258) is a single-chain monoclonal antibody against all isoforms of VEGF-A. It has the advantage, compared to other drugs, of being a small molecule that penetrates the retina very well. It disappears immediately from the blood circulation, thus reducing the risk of systemic side effects. The clinical trials that provided this information on brolucizumab are called HAWK and HARRIER and enrolled 1,800 patients worldwide. Most patients are initially treated with three doses monthly. Subsequently, an intravitreal injection was given every three months, every two months in a small percentage of cases. Timely intervention in the treatment of exudative maculopathy is always essential. As soon as the liquid reappears inside the retina, intravitreal injections are administered. The key to success in the treatment of exudative maculopathy is to prevent the reappearance of intraretinal fluid or to intervene as soon as it occurs. The new therapy for exudative maculopathy, brolucizumab, is expected to be marketed in the coming months. We will publish further information on the availability of this drug in the near future.